ARFGAP3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB100-843
Key Product Details
Species Reactivity
Validated:
Mouse
Predicted:
Bovine (100%), Canine (100%), Human (100%), Rat (100%). Backed by our 100% Guarantee.
Applications
Peptide ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence C-NGVVTSIQDRYGS corresponding to C-Terminus according to NP_055385.3, NP_001135765.1.
Specificity
This antibody is expected to recognize both reported isoforms (NP_055385.3; NP_001135765.1).
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for ARFGAP3 Antibody
Western Blot: ARFGAP3 Antibody [NB100-843]
Western Blot: ARFGAP3 Antibody [NB100-843] - (2ug/ml) of mouse brain extracts (RIPA buffer, 35ug total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence.Applications for ARFGAP3 Antibody
Application
Recommended Usage
Peptide ELISA
Detection limit 1:8000
Western Blot
1 - 3 ug/ml
Application Notes
WB: Approx. 55-60 kDa band observed in mouse brain extracts.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: ARFGAP3
Alternate Names
ADP-ribosylation factor GTPase activating protein 1, ADP-ribosylation factor GTPase activating protein 3, ADP-ribosylation factor GTPase-activating protein 3, ARF GAP 3, ARFGAP1, FLJ45618
Gene Symbol
ARFGAP1
UniProt
Additional ARFGAP3 Products
Product Documents for ARFGAP3 Antibody
Product Specific Notices for ARFGAP3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...